Withdrawal of Alupent

The short-acting bronchodilator orciprenaline sulphate (Alupent) is to be withdrawn over the next year, following an unfavourable risk-benefit analysis by the MHRA.

It concluded that the adverse events associated with the drug outweigh its clinical benefits.

Patients who are currently receiving Alupent should be switched to a more selective ß2-agonist, such as salbutamol or terbutaline, as soon as possible.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

A woman leans on a desk holding her stomach in pain.

Draft NICE approval for new fibroid treatment

Around 4500 women in England and Wales will be eligible...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...